^
Association details:
| Biomarker: | EGFR exon 19 deletion + TP53 mutation + CDK6 amplification + KRAS amplification |
|---|---|
| Cancer: | Lung Non-Small Cell Squamous Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Autopsy and Next Generation Sequencing Report of First-Line Treatment with Osimertinib for EGFR-Mutated Squamous Cell Carcinoma of the Lung
Published date:
08/08/2023
Excerpt:
The patient was an 83-year-old male. He was diagnosed with SCC of the lung, and molecular analysis revealed that the tumor was positive for EGFR exon19 deletion. He was treated with osimertinib 80 mg/day….The case was categorized as a progressive disease. The patient died 3 weeks later....Next-generation sequencing showed multiple genetic abnormalities, including TP53 mutation and amplification of CDK6 and KRAS, which have previously been associated with resistance to osimertinib....The current case report shows that next-generation sequencing can explain why osimertinib is ineffective in EGFR-mutated SCC.
